Predictive biomarkers of pre-eclampsia and effectiveness of preventative interventions for the disease

Bibliography

• World Health Organization. The world health report: 2005: make every mother and child count. WHO, Geneve; 2005
   Google Scholar
• American College of Obstetricians and Gynecologists; task force on hypertensionin pregnancy hypertension in pregnancy. Report of the American College of Obstetricians and Gynecologists task force on hypertension in pregnancy. Obstet Gynecol 2013;122(5):1122-31
   Google Scholar
• Goldenberg RL, Culhane JF, Iams JD, et al. Epidemiology and causes of preterm birth. Lancet 2008;371:75-84
   PubMed Web of Science ®Google Scholar
• Repke J. What is new in Preeclampsia? Obstet Gynecol 2013;121:682-3
   PubMed Web of Science ®Google Scholar
• Conde-Agudelo A, Villar J, Lindheimer M. World Health Organization systematic review of screening tests for preeclampsia. Obstet Gynecol 2004;104:1367-91
   PubMed Web of Science ®Google Scholar
• Caritis S, Sibai B, Hauth J, et al. Predictors of pre-eclampsia in women at high risk. National Institute of Child Health and Human Development Network of Maternal-Fetal Medicine Units. Am J Obstet Gynecol 1998;179:946-51
   PubMed Web of Science ®Google Scholar
• Myatt L, Miodovnik M. Prediction of preeclampsia. Semin Perinatol 1999;23:45-57
   PubMed Web of Science ®Google Scholar
• Poon LC, Kametas NA, Chelemen T, et al. Maternal risk factors for hypertensive disorders in pregnancy: a multivariate approach. J Hum Hypertens 2010;24:104-10
   PubMed Web of Science ®Google Scholar
• Wright D, Akolekar R, Syngelaki A, et al. A competing risks model for early screening for preeclampsia. Fetal Diagn Ther 2012;32:171-8
   PubMed Web of Science ®Google Scholar
• Cnossen JS, Morris RK, ter Riet G, et al. Use of uterine artery Doppler ultrasonography to predict pre-eclampsia and intrauterine growth restriction: a systematic review and bivariable metanalysis. CMAJ 2008;178:701-11
   PubMed Web of Science ®Google Scholar
• Papageorghiou AT, Yu CK, Bindra R, et al. Multicenter screening for pre-eclampsia and fetal growth restriction by transvaginal uterine artery Doppler at 23 weeks of gestation. Ultrasound Obstet Gynecol 2001;18:441-9
   PubMed Web of Science ®Google Scholar
• Myatt L, Clifton GR, Roberts MJ. The utility of Uterine Artery Doppler Velocimetry in Prediction of Pre-eclampsia in a Low Risk Population. Obstet Gynecol 2012;120(4):815-22
   PubMed Web of Science ®Google Scholar
• Gallo DM, Poon LC, Akolekar R, et al. Prediction fo Preeclampsia by Uterine Artery Doppler at 20–24 weeks' gestation. Fetal Diagn Ther 2013;34:241-7
   PubMed Web of Science ®Google Scholar
• Khalil A, Nicolaides KH. How to record uterine artery Doppler in the first trimester. Ultrasound Obstet Gynecol 2013;42:478-9
   PubMed Web of Science ®Google Scholar
• Pedrosa AC, Matias A. Screening for pre-eclampsia: a systematic review of tests combining uterine artery Doppler with other markers. J Perinat Med 2011;39:619-35
   PubMed Web of Science ®Google Scholar
• Verlohren S, Melchiorre K, Khalil A, et al. Uterine artery Doppler, birthweight and timing of preeclampsia onset: providing new insights into the dual etiology of late onset preeclampsia. Ultrasound Obstet Gynecol 2014. [ Epub ahead of print]
   Web of Science ®Google Scholar
• Cetin I, Huppertz B, Burton G, et al. Pregenesys pre-eclampsia markers consensus meeting: what do we require from markers, risk assessment and model systems to tailor preventive strategies? Placenta 2011;32(Suppl):S4-16
   PubMed Web of Science ®Google Scholar
• Than NG, Romero R, Goodman M, et al. A primate subfamily of galectins expressed at the maternal-fetal interface that promote immune cell death. Proc Natl Acad Sci USA 2009;106:9731-6
   PubMed Web of Science ®Google Scholar
• Huppertz B, Kawaguchi R. First trimester serum markers to predict preeclampsia. Wien Med Wochenschr 2012;162:191-5
   PubMedGoogle Scholar
• Huppertz B, Sammar M, Chefetz I, et al. Longitudinal determination of serum placental protein 13 during development of preeclampsia. Fetal Diagn Ther 2008;24:230-6
   PubMed Web of Science ®Google Scholar
• Huppertz B, Meiri H, Gizurarson S, et al. Placental protein 13 (PP13): a new biological target shifting individualized risk assessment to personalized drug design combating pre-eclampsia. Hum Reprod Update 2013;19:391-405
   PubMed Web of Science ®Google Scholar
• Meiri H, Sammar M, Herzog A, et al. Prediction of preeclampsia by placental protein 13 and background risk factors and its prevention by aspirin. J Perinat Med 2014. [ Epub ahead of print]
   PubMed Web of Science ®Google Scholar
• Goetzinger KR, Singla A, Gerkowicz S, et al. Predicting the risk of preeclampsia between 11 and 13 weeks' gestation by combining maternal characteristics and serum analytes, PAPP-A and free beta hCG. Prenat Diagn 2010;30:1138-42
   PubMed Web of Science ®Google Scholar
• Goetzinger KR, Zhong Y, Cahill AG, et al. Efficiency of first trimester uterine artery Doppler, a disintegrin and metalloprotease 12, pregnancy associated plasma protein A, and maternal characteristics in the prediction of preeclampsia. J Ultrasound Med 2013;32:1593-600
   PubMed Web of Science ®Google Scholar
• Odibo AO, Zhong Y, Longtine M, et al. First-trimester serum analytes, biophysical tests and the association with pathological morphometry in the placenta of pregnancies with preeclampsia and fetal growth restriction. Placenta 2011;32:333-8
   PubMed Web of Science ®Google Scholar
• Purwosunu Y, Sekizawa A, Yoshimura S, et al. Expression of angiogenesis-related genes in the cellular component of the blood of preeclamptic women. Reprod Sci 2009;16:857-64
   PubMed Web of Science ®Google Scholar
• Levine RJ, Maynard SE, Qian C, et al. Circulating angiogenic factors and the risk of preeclampsia. N Engl J Med 2004;350:672-83
   PubMed Web of Science ®Google Scholar
• Kleinrouweler CE, Wiegerinck MM, Ris-Stalpers C, et al. Accuracy of circulating placental growth factor, vascular endothelial growth factor, soluble fms-like tyrosine kinase 1 and soluble endoglin in the prediction of pre-eclampsia: a systematic review and meta-analysis. BJOG 2012;119:778-87
   PubMed Web of Science ®Google Scholar
• Myers J, Kenny L, McCowan L, et al. Angiogenic factors combined with clinical risk factors to predict preterm pre-eclampsia in nulliparous women: a predictive test accuracy study. BJOG 2013;120:1215-23
   PubMed Web of Science ®Google Scholar
• Maynard SE, Crawford SL, Bathgate S, et al. Gestational angiogenic biomarker patterns in high risk preeclampsia groups. Am J Obstet Gynecol 2013;209:53.e1-9
   PubMed Web of Science ®Google Scholar
• Brookes K, Cummings J, Backen A, et al. Issues on fit-for-purpose validation of a panel of ELISAs for application as biomarkers in clinical trials of anti-Angiogenic drugs. Br J Cancer 2010;102:1524-32
   PubMed Web of Science ®Google Scholar
• Stepan H, Krämer T, Faber R. Maternal plasma concentrations of soluble endoglin in pregnancies with intrauterine growth restriction. J Clin Endocrinol Metab 2007;92:2831-4
   PubMed Web of Science ®Google Scholar
• Alahakoon TI, Zhang W, Trudinger BJ, et al. Discordant clinical presentations of preeclampsia and intrauterine fetal growth restriction with similar pro- and anti-angiogenic profiles. J Matern Fetal Neonatal Med 2014. [ Epub ahead of print]
   PubMedGoogle Scholar
• Boij R, Svensson J, Nilsson-Ekdahl K, et al. Biomarkers of coagulation, inflammation and angiogenesis are independently associated with preeclampsia. Am J Reprod Immunol 2012;68:258-70
   PubMed Web of Science ®Google Scholar
• Redman CW, Sargent IL, Staff AC. IFPA senior award lecture: making sense of pre-eclampsia – two placental causes of pre-eclampsia? Placenta 2014. [ Epub ahead of print]
   Web of Science ®Google Scholar
• Barsoum IB, Renaud SJ, Graham CH. Glyceril Trinitrate inhibits hypoxia – induced release of soluble fms-like tyrosine kinase 1 and endoglin from placental tissue. Am J Pathol 2011;178:2888-96
   PubMed Web of Science ®Google Scholar
• Ashur-Fabian O, Yerushalmi GM, Mazaki-Tovi S, et al. Cell free expression of hif1α and p21 in maternal peripheral blood as a marker for preeclampsia and fetal growth restriction. PLoS One 2012;7:e37273
   PubMed Web of Science ®Google Scholar
• Tal R. The role of hypoxia and hypoxia-inducible factor-1alpha in preeclampsia pathogenesis. Biol Reprod 2012;87:134
   PubMed Web of Science ®Google Scholar
• Nevo O, Soleymanlou N, Wu Y, et al. Increased expression of sFlt-1 in in vivo and in vitro models of human placental hypoxia is mediated by HIF-1. Am J Physiol Regul Integr Comp Physiol 2006;291:R1085-93
   PubMed Web of Science ®Google Scholar
• Sánchez-Elsner T, Botella LM, Velasco B, et al. Endoglin expression is regulated by transcriptional cooperation between the hypoxia and transforming growth factor-beta pathways. J Biol Chem 2002;277:43799-808
   PubMed Web of Science ®Google Scholar
• Yinon Y, Nevo O, Xu J, et al. Severe intrauterine growth restriction pregnancies have increased placental endoglin levels: hypoxic regulation via transforming growth factor-beta 3. Am J Pathol 2008;172:77-85
   PubMed Web of Science ®Google Scholar
• Centlow M, Carninci P, Nemeth K, et al. Placental expression profiling in preeclampsia: local overproduction of haemoglobin may drive pathological changes. Fertil Steril 2008;90:1834-43
   PubMed Web of Science ®Google Scholar
• May K, Rosenlof L, Olsson MG, et al. Perfusion of human placenta with haemoglobin introduces preeclampsia-like injuries that are prevented by alpha(1)macroglobulin. Placenta 2011;32:323-32
   PubMed Web of Science ®Google Scholar
• Olsson MG, Centlow M, Rutardottir S, et al. Increased levels of cell-free hemoglobin, oxidation markers, and the antioxidative heme scavenger a1-microglobulin in preeclampsia. Free Radic Biol Med 2010;48(2):284e91
   Google Scholar
• Anderson UD, Olsson MG, Rutardottir S, et al. Fetal hemoglobin and alpha 1-microglobulin as first and early second trimester predictive biomarkers for preeclampsia. Am J Obstet Gynecol 2011;204:520.e1-520.e5
   PubMed Web of Science ®Google Scholar
• Fanos V, Atzori L, Makarenko K, et al. Metabolomics application in maternal-fetal medicine. Biomed Res Int 2013;2013:720514
   PubMed Web of Science ®Google Scholar
• Bahado-Singh RO, Akolekar R, Mandal R, et al. Metabolomics and first trimester prediction of early preeclampsia. J Maternal Fetal Neonatal Med 2012;25:1840-7
   PubMed Web of Science ®Google Scholar
• Bahado-Singh RO, Akolekar R, Mandal R, et al. First-trimester metabolomics detection of late-onset preeclampsia. Am J Obstet Gynecol 2013;208(1):58.e1-7
   PubMed Web of Science ®Google Scholar
• Bain JR, Stevens RD, Wenner BR, et al. Metabolomics applied to diabetes research: moving from information to knowledge. Diabetes 2009;58:2429-43
   PubMed Web of Science ®Google Scholar
• Holmes E, Wilson ID, Nicholson JK. Metabolic phenotyping in health and disease. Cell 2008;134:714-17
   PubMed Web of Science ®Google Scholar
• Chan Leung TN, Zhang J, Lau TK, et al. Increased maternal plasma fetal DNA concentrations in women who eventually develop preeclampsia. Clin Chem 2001;47:137-9
   PubMed Web of Science ®Google Scholar
• Smid M, Vassallo A, Lagona F, et al. Quantitative analysis of fetal DNA in maternal plasma in pathological conditions associated with placental abnormalities. Ann NY Acad Sci 2001;945:132-7
   PubMed Web of Science ®Google Scholar
• Smid M, Galbiati S, Lojacono A, et al. Correlation of fetal DNA levels in maternal plasma with Doppler status in pathological pregnancies. Prenat Diagn 2006;26:785-90
   PubMed Web of Science ®Google Scholar
• Illanes S, Parra M, Serra R, et al. Increased free fetal DNA levels in early pregnancy plasma of women who subsequently develop preeclampsia and intrauterine growth restriction. Prenat Diagn 2009;29:1118-22
   PubMed Web of Science ®Google Scholar
• Galbiati S, Causarano V, Pinzani P, et al. Evaluation of a panel of circulating DNA, RNA and protein potential markers of pregnancy pathologies. Clin Chem Lab Med 2010;48:791-4
   PubMed Web of Science ®Google Scholar
• Tsui DW, Chan KC, Chim SS, et al. Quantitative aberrations of hypermethylated RASSF1A gene sequences in maternal plasma in pre-eclampsia. Prenat Diagn 2007;27:1212-18
   PubMed Web of Science ®Google Scholar
• Chan KC, Ding C, Gerovassili A, et al. Hypermethylated RASSF1A in maternal plasma: a universal fetal DNA marker that improves the reliability of noninvasive prenatal diagnosis. Clin Chem 2006;52:2211-18
   PubMed Web of Science ®Google Scholar
• Papantoniou N, Bagiokos V, Agiannitopoulos K, et al. RASSF1A in maternal plasma as a molecular marker of preeclampsia. Prenat Diagn 2013;33:682-7
   PubMed Web of Science ®Google Scholar
• Ng EK, Leung TN, Tsui NB, et al. The concentration of circulating corticotropin-releasing hormone mRNA in maternal plasma is increased in preeclampsia. Clin Chem 2003;49:727-31
   PubMed Web of Science ®Google Scholar
• Purwosunu Y, Sekizawa A, Farina A, et al. Cell-free mRNA concentrations of CRH, PLAC1, and selectin-P are increased in the plasma of pregnant women with preeclampsia. Prenat Diagn 2007;27:772-7
   PubMed Web of Science ®Google Scholar
• Poon LC, Kametas NA, Maiz N, et al. First trimester prediction of hypertensive disorder in pregnancy. Hypertension 2009;53:812-18
   PubMed Web of Science ®Google Scholar
• Akolekar R, Syngelaki A, Sarquis R, et al. Prediction of early, intermediate and late pre-eclampsia from maternal factors, biophysical and biochemical markers at 11 – 13 weeks. Prenat Diagn 2011;31:66-74
   PubMed Web of Science ®Google Scholar
• Wright D, Akolekar R, Syngelaki A, et al. A competing risk model in early screening for preeclampsia. Fetal Diagn Ther 2012;32:171-8
   PubMed Web of Science ®Google Scholar
• Myatt L, Clifton RG, Roberts IM, et al. First trimester prediction of preeclampsia in nulliparous women at low risk. Obstet Gynecol 2012;119:1234-42
   PubMed Web of Science ®Google Scholar
• Scazzocchio E, Figueras F, Crispi F, et al. Performance of a first-trimester screening of preeclampsia in a routine care low-risk setting. Am J Obstet Gynecol 2013;208(3):203.e1-203.e10
   PubMed Web of Science ®Google Scholar
• Akolekar R, Syngelaki A, Poon L, et al. Competing risks model in early screening for preeclampsia by biophysical and biochemical markers. Fetal Diagn Ther 2013;33:8-15
   PubMed Web of Science ®Google Scholar
• Park HJ, Kim SH, Jung YW, et al. Screening models using multiple markers for early detection of late-onset pre-eclampsia in low-risk pregnancy. BMC Pregnancy Childbirth 2014;14(1):35
   PubMedGoogle Scholar
• Schiff E, Peleg E, Goldenberg M, et al. The use of aspirin to prevent pregnancy-induced hypertension and lower the ratio of thromboxane A2 to prostacyclin in relatively high risk pregnancies. N Engl J Med 1989;321:351-6
   PubMed Web of Science ®Google Scholar
• CLASP (Collaborative Low-dose Aspirin Study in Pregnancy) Collaborative Group. CLASP: a randomized trial of low-dose aspirin for prevention and treatment of pre-eclampsia among 9364 pregnant women. Lancet 1994;343:619-29
   PubMed Web of Science ®Google Scholar
• Duley L, Henderson-Smart DJ, Meher S, et al. Antiplatelet agents for preventing pre-eclampsia and its complications. Cochrane Database Syst Rev 2007(2):CD004659
   PubMed Web of Science ®Google Scholar
• Roberge S, Nicolaides KH, Demers S, et al. Prevention of perinatal death and adverse perinatal outcome using low dose aspirin: a meta-analysis. Ultrasound Obstet Gynecol 2013;41:491-9
   PubMed Web of Science ®Google Scholar
• Steegers E, Dadelszen P, Duvekot J, et al. Preeclampsia. Lancet 2010;376:631-4
   PubMed Web of Science ®Google Scholar
• Dodd JM, McLeod A, Windrim RC, et al. Antithrombotic therapy for improving maternal or infant health outcomes in women considered at risk of placental dysfunction. Cochrane Database Syst Rev 2010(6):CD006780
   Google Scholar
• Villar J, Belizàn JM. Same nutrients, different hypotheses: disparity in trials of calcium supplementation during pregnancy. Am J Clin Nutr 2000;71(Suppl 5):1375S-9S
   PubMed Web of Science ®Google Scholar
• Hofmeyr GJ, Atallah AN, Duley L. Calcium supplementation during pregnancy for preventing hypertensive disorders and related problems. Cochrane Database Syst Rev 2006(3):CD001059
   Google Scholar
• Levine RJ, Hauth JC, Curet LB, et al. Trial of calcium to prevent preeclampsia. N Engl J Med 1997;337:69-76
   PubMed Web of Science ®Google Scholar
• Hofmeyr GJ, Lawrie TA, Atallah AN, et al. Calcium supplementation during pregnancy for preventing hypertensive disorders and related problems. Cochrane Database Syst Rev 2010;4(8):CD001059
   Google Scholar
• Von Dadelszen P, Firoz T, Donnay F, et al. Preeclampsia in low and middle income countries-health services lessons learned from the PRE-EMPT (PRE-Eclampsia-eclampsia monitoring, prevention and treatment) project. J Obstet Gynaecol Can 2012;34:917-26
   PubMedGoogle Scholar
• Roberts JM, Myatt L, Spong CY, et al. Vitamins C and E to prevent complications of pregnancy-associated hypertension. Eunice Kennedy Shriver National Institute of Child Health and Human Development Maternal-Fetal Medicine Units Network. N Engl J Med 2010;362:1282-91
   PubMed Web of Science ®Google Scholar
• Mogollon JA, Boivin C, Philippe K, et al. Consumption of chocolate in pregnant women and risk of preeclampsia: a systematic review. Syst Rev 2013;2:114
   PubMedGoogle Scholar
• Triche EW, Grosso LM, Belanger K, et al. Chocolate consumption in pregnancy and reduced likelihood of preeclampsia. Epidemiology 2008;19:459-64
   PubMed Web of Science ®Google Scholar
• Klebanoff MA, Zhang J, Zhang C, et al. Maternal serum teobromine and the development of preeclampsia. Epidemiology 2009;20:727-32
   PubMed Web of Science ®Google Scholar
• Saftlas AF, Triche EW, Beydoun H, et al. Does chocolate intake during pregnancy reduce the risks of preeclampsia and gestational hypertension? Ann Epidemiol 2010;20:584-91
   PubMed Web of Science ®Google Scholar
• Bhattacharya S, Campbell D. ListonW. Effect of body mass index on pregnancy outcomes in nulliparous women delivering singleton babies. BMC Public Health 2007;7:168
   PubMed Web of Science ®Google Scholar
• Ferland S, Bujold E, Giguère Y, et al. Association between physical activity in early pregnancy and markers of placental growth and function. J Obstet Gynaecol Can 2013;35:787-92
   PubMedGoogle Scholar
• Kasawara KT, Burgos CS, do Nascimento SL, et al. Maternal and Perinatal Oucomes of Exercise in pregnant women with Chronic Hypertension and/or Previous Preeclampsia: a Randomized Controlled Trial. ISRN Obstet Gynecol 2013;2013:857047
   Google Scholar
• Bezerra Maia E Holanda Moura S, Marques Lopes L, Murthi P, et al. Prevention of preeclampsia. J Pregnancy 2012;2012:435090
   Google Scholar
• Meher S, Duley L. Nitric oxide for preventing preeclampsia and its complications. Cochrane Database Syst Rev 2007(2):CD006490
   Google Scholar
• Thadhani R, Kisner T, Hagmann H, et al. Pilot study of extracorporeal removal of soluble fms-like tyrosine kinase 1 in preeclampsia. Circulation 2011;124:940-50
   PubMed Web of Science ®Google Scholar
• Li Z, Zhang Y, Ying Ma J, et al. Recombinant vascular endothelial growth factor 121 attenuates hypertension and improves kidney damage in a rat model of preeclampsia. Hypertension 2007;50:686-92
   PubMed Web of Science ®Google Scholar
• Gizurarson S, Huppertz B, Osol G, et al. Effects on placental protein 13 on cardiovascular system in gravid and non-gravid rodents. Fetal Diagn Ther 2013;33:257-64
   PubMed Web of Science ®Google Scholar
• Hansson SR, Gram M, Akerström B. Fetal haemoglobin in preeclampsia: a new causative factor, a tool for prediction/diagnosis and a potential target for therapy. Curr Opin Obstet Gynecol 2013;25:448-55
   PubMed Web of Science ®Google Scholar
• James JL, Srinivasan S, Alexander M, et al. Can we fix it? Evaluating the potential of placental stem cells for the treatment of pregnancy disorders. Placenta 2014;35:77-84
   PubMed Web of Science ®Google Scholar
• Schumacher B, Moise KJ Jr. Fetal transfusion for red blood cell alloimmunization in pregnancy. Obstet Gynecol 1996;88:137-50
   PubMed Web of Science ®Google Scholar
• Fraser A, Nelson SM, Macdonald-Wallis C, et al. Associations of pregnancy complications with calculated cardiovascular disease risk and cardiovascular risk factors in middle age: the Avon Longitudinal Study of Parents and Children. Circulation 2012;125:1367-80
   PubMed Web of Science ®Google Scholar